1Goudas LC,Bioch R,Gialel i-Qoudas M,et al.The epidemiology of cancer pain[J].Cancer Invest,2005,25(2):182-190.
2Mercadante S.Predictive factors and opioid responsiveness in cancer pain[J].Eur J Cancer,1996,34(5):627-651.
3Coluzzi F,Mattia C.Mechanism-based treatment in chronic neuropathic pain:the role of antidepressants[J].Curr Pharm Des,2005,11(23):2945-2960.
4Mercadante S,Arcuri E,Tirelli W,et al.Amitriptyline in neuropathic cancer pain in patients on morphine therapy:a randomized placebo-controlled,double-blind crossover study[J].Tumori,2002,88(3):239-242.
5Epstein JB,Epstein JD,Epstein MS,et al.Doxepin rinse for management of mucositis pain in patients with cancer:one week follow-up of topical therapy[J].Spec Care Dentist,2008,28(2):73-77.
6Goldstein DJ,Lu Y,Detke MJ,et al.Duloxetine vs.placebo in patients with painful diabetic neuropathy[J].Pain,2005,116(1-2):109-118.
7Matsuoka H,Makimura C,Koyama A,et al.Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin[J].Anticancer Res,2012,32(5):1805-1809.
8Rowbotham MC,Goli V,Kunz NR,et al.Venlafaxine extended release in the treatment of painful diabetic neuropathy:a doubleblind,placebo-controlled study[J].Pain,2004,110(3):697-706.
9Angelo LJ,Lee KC.Dose-related paresthesias with venlafaxine[J].J Pharm Pract,2013,26(5):514-517.
10Durand JP,Deplanque G,Montheil V,et al.Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity:results of EFFOX,a randomized,double-blind,placebo-controlled phase III trial[J].Ann Oncol,2012,23(1):200-205.
